BiotechTube

Abemaciclib + Darolutamide + LHRH agonist/antagonist

Phase 1Completed
2 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostatic Neoplasms

Conditions

Prostatic Neoplasms

Trial Timeline

Jan 12, 2024 → Jan 21, 2026

NCT ID
NCT05999968

About Abemaciclib + Darolutamide + LHRH agonist/antagonist

Abemaciclib + Darolutamide + LHRH agonist/antagonist is a phase 1 stage product being developed by Eli Lilly for Prostatic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT05999968. Target conditions include Prostatic Neoplasms.

What happened to similar drugs?

15 of 20 similar drugs in Prostatic Neoplasms were approved

Approved (15) Terminated (0) Active (5)
✅Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
✅Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
✅Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
✅Tamsulosin OCASAstellas PharmaApproved
✅Tamsulosin OCAS + PlaceboAstellas PharmaApproved
✅TadalafilEli LillyApproved
✅ErtapenemMerckApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05999968Phase 1Completed

Competing Products

20 competing products in Prostatic Neoplasms

See all competitors
ProductCompanyStageHype Score
Tadalafil + PlaceboEli LillyPhase 3
40
Placebo + tadalafilEli LillyPhase 3
40
Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
43
tadalafil + placeboEli LillyPhase 2
35
Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue MedicationDaiichi SankyoPhase 1/2
39
Enzalutamide + Abiraterone acetateAstellas PharmaPre-clinical
26
Placebo tamsulosin hydrochloride OCAS 0.4 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg + tamsulosin hydrochloride OCAS 0.4 mg + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
40
Novel hormonal therapyAstellas PharmaPre-clinical
26
ASP3550Astellas PharmaPhase 2
35
Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
43
Novel hormonal therapyAstellas PharmaPre-clinical
26
tamsulosin 0.4mgAstellas PharmaPre-clinical
22
Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
43
Enzalutamide + NSAA + LHRHA or Surgical CastrationAstellas PharmaPhase 3
44
enzalutamide + bicalutamideAstellas PharmaPhase 2
35
Tamsulosin OCASAstellas PharmaApproved
43
degarelixAstellas PharmaPhase 2
35
Tamsulosin OCAS + PlaceboAstellas PharmaApproved
43
Tadalafil + PlaceboEli LillyPhase 2
35
TadalafilEli LillyApproved
43